Pays: Canada
Langue: français
Source: Health Canada
Méloxicam
CHANELLE PHARMACEUTICALS MANUFACTURING LIMITED
20MG
Solution
Méloxicam 20MG
Intraveineuse
20/50/100/250ML
Prescription
Bétails; Porcs; Mouton
Numéro de groupe d'ingrédients actifs (GIA) :0131676007
APPROUVÉ
2020-05-20
PACKAGE LEAFLET VDD VERSION 18JAN2021 CHANELLE PHARMACEUTICALS MANUFACTURING LTD VERSION DATE 18JAN2021 Pr RHEUMOCAM INJECTION MELOXICAM INJECTION 20 MG/ML VETERINARY USE ONLY DIN 02452146 Sterile Each mL contains 20 mg meloxicam and 150 mg ethanol, as preservative. THERAPEUTIC CLASSIFICATION: Non-steroidal anti-inflammatory drug (NSAID). INDICATIONS: CATTLE: As an aid in improving appetite and weight gains when administered at the onset of diarrhoea, in combination with oral rehydration therapy, in calves over one week of age. For relief of pain following de-budding of horn buds in calves less than 3 months of age. For the symptomatic treatment of inflammation and pain associated with acute clinical mastitis. For the reduction of pain associated with abdominal surgery such as caesarean section. SHEEP: For single dose use in sheep and lambs 14 days of age or older for the alleviation of pain and inflammation. SWINE: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. DOSAGE AND ADMINISTRATION: CATTLE: Single subcutaneous or intravenous injection of 0.5 mg meloxicam/kg body weight (2.5 mL/100 kg body weight). For reduction in pain associated with abdominal surgery administer 10 to 20 minutes before the painful procedure. SHEEP: Single subcutaneous injection administered 15-30 minutes prior to painful procedure. Inject the product high on the neck behind the ear at a dose of 1.0 mg meloxicam/kg body weight (1.0 mL/20 kg). SWINE: Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (2.0 mL/100 kg). If required, a second administration of meloxicam can be given after 24 hours. CONTRAINDICATIONS: Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders or where there is individual hypersensitivity to the product. Do not administer concurrently with steroidal, other non- steroidal anti-inflammatory drugs or with anti-coagulant agents. C Lire le document complet